Studying significance of apoptosis in mediating tolbutamide-induced teratogenesis in vitro

Fundamental and Clinical Pharmacology

Volumn 26, Issue 4, 2012, Pages 484-494

  Singh, Gyanendra ^a,b   Kumar, Akhilesh ^a   Sinha, Neeraj ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Embryo culture; In vitro; Tolbutamide

Indexed keywords

TOLBUTAMIDE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CONGENITAL MALFORMATION; CONTROLLED STUDY; DNA FRAGMENTATION; EMBRYO; EMBRYO DEVELOPMENT; EMBRYO GROWTH; FLOW CYTOMETRY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; TERATOGENESIS;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; APOPTOSIS; DNA; DNA FRAGMENTATION; EMBRYO, MAMMALIAN; NERVOUS SYSTEM MALFORMATIONS; RATS; TOLBUTAMIDE;

EID: 84863541683     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00946.x     Document Type: Article

References (57)

1. Arends M.J., Wyllie A.H. Apoptosis: mechanisms and roles in pathology. Int. Rev. Exp. Pathol. (1991) 32 223-254.
2. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science (1995) 267 1456-1462.
3. Lee Q.P., Park H.W., Thayer J., Mirkes P.E., Juchau M.R. Apoptosis induced in cultured rat embryos by intra-amniotically microinjected sodium nitroprusside. Teratology (1996) 53 21-30.
4. Dong J., Sulik K.K., Chen S.Y. The role of NOX enzymes in ethanol-induced oxidative stress and apoptosis in mouse embryos. Toxicol. Lett. (2010) 193 94-100.
5. Hansen J.M. Oxidative stress as a mechanism of teratogenesis. Birth Defects Res. C Embryo Today (2006) 78 293-307.
6. Pekar O., Molotski N., Savion S., Fein A., Toder V., Torchinsky A. p53 regulates cyclophosphamide teratogenesis by controlling caspases 3, 8, 9 activation and NF-kappaB DNA binding. Reproduction (2007) 134 379-388.
7. Sarkar S.A., Sharma R.P. Expression of c-Myc and other apoptosis-related genes in Swiss Webster mouse fetuses after maternal exposure to all trans-retinoic acid. Reprod. Toxicol. (2002) 16 245-252.
8. Kerr J.F. Shrinkage necrosis: a distinct mode of cellular death. J. Pathol. (1971) 105 13-20.
9. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer (1972) 26 239-257.
10. Smoak I.W. Teratogenic effects of tolbutamide on early-somite mouse embryos in vitro. Diabetes Res. Clin. Pract. (1992) 17 161-167.
11. Belisle R.J., Long S.Y. Tolbutamide treatment of pregnant mice: repeated administration reduces fetal lethality. Teratology (1976) 13 65-70.
12. McColl J.D., Robinson S., Globus M. Effect of some therapeutic agents on the rabbit fetus. Toxicol. Appl. Pharmacol. (1967) 10 244-252.
13. Smithberg M., Runner M.N. Teratogenic effects of hypoglycemic treatments in inbred strains of mice. Am. J. Anat. (1963) 113 479-489.
14. Mills J.L., Baker L., Goldman A.S. Malformations in infants of diabetic mothers occur before the seventh gestational week. Implications for treatment. Diabetes (1979) 28 292-293.
15. Ito T., Ando H., Suzuki T. et al. Identification of a primary target of thalidomide teratogenicity. Science (2010) 327 1345-1350.
16. Miller M.T., Stromland K. Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses. Teratology (1999) 60 306-321.
17. Stromland K., Pinazo-Duran M.D. Ophthalmic involvement in the fetal alcohol syndrome: clinical and animal model studies. Alcohol Alcohol. (2002) 37 2-8.
18. Therapontos C., Erskine L., Gardner E.R., Figg W.D., Vargesson N. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc. Natl. Acad. Sci. USA (2009) 106 8573-8578.
19. Coopersmith H., Kerbel N.C. Drugs and congenital anomalies. Can. Med. Assoc. J. (1962) 87 193.
20. Larsson Y., Sterky G. Possible teratogenic effect of tolbutamide in pregnant prediabeti. Lancet (1960) 2 1424-1425.
21. Schiff D., Aranda J.V., Stern L. Neonatal thrombocytopenia and congenital malformations associated with administration of tolbutamide to the mother. J. Pediatr. (1970) 77 457-458.
22. Soler N.G., Walsh C.H., Malins J.M. Congenital malformations in infants of diabetic mothers. Q. J. Med. (1976) 45 303-313.
23. Lowy C., Beard R.W., Goldschmidt J. Congenital malformations in babies of diabetic mothers. Diabet. Med. (1986) 3 458-462.
24. Dolger H., Bookman J.J., Nechemias C. Tolbutamide in pregnancy and diabetes. J. Mt. Sinai Hosp. N. Y. (1969) 36 471-474.
25. Malins J.M., Cooke A.M., Pyke D.A., Fitzgerald M.G. Sulphonylurea drugs in pregnancy. Br. Med. J. (1964) 2 187.
26. Notelovitz M. Sulphonylurea therapy in the treatment of the pregnant diabetic. S. Afr. Med. J. (1971) 45 226-229.
27. Piacquadio K., Hollingsworth D.R., Murphy H. Effects of in-utero exposure to oral hypoglycaemic drugs. Lancet (1991) 338 866-869.
28. Ferner R.E., Neil H.A. Sulphonylureas and hypoglycaemia. Br. Med. J. (Clin. Res. Ed.). (1988) 296 949-950.
29. Akazawa M., Akazawa S., Hashimoto M. et al. Effects of brief exposure to insulin-induced hypoglycemic serum during organogenesis in rat embryo culture. Diabetes (1989) 38 1573-1578.
30. Buchanan T.A., Schemmer J.K., Freinkel N. Embryotoxic effects of brief maternal insulin-hypoglycemia during organogenesis in the rat. J. Clin. Invest. (1986) 78 643-649.
31. Smoak I.W., Sadler T.W. Embryopathic effects of short-term exposure to hypoglycemia in mouse embryos in vitro. Am. J. Obstet. Gynecol. (1990) 163 619-624.
32. Ellis-Hutchings R.G., Carney E.W. Whole embryo culture: a "New" technique that enabled decades of mechanistic discoveries. Birth Defects Res. B Dev. Reprod. Toxicol. (2010) 89 304-312.
33. Luijten M., van Beelen V.A., Verhoef A. et al. Transcriptomics analysis of retinoic acid embryotoxicity in rat postimplantation whole embryo culture. Reprod. Toxicol. (2010) 30 333-340.
34. Singh G., Sinha N. Involvement of apoptosis in mediating mitomycin C-induced teratogenesis in vitro. Toxicol. Mech. Methods (2010) 20 190-196.
35. Singh G., Sinha N., Koushik C.J., Mathur S.K., Srivastava S. Detecting role of apoptosis in mediating cyclophosphamide induced teratogenesis in vitro. Toxicol. Mech. Methods (2005) 15 391-397.
36. Singh G., Sinha N., Mahipag G.S. Role of apoptosis in mediating salicylic acid-induced teratogenesis in vitro. Toxicol. Mech. Methods (2009) 19 161-168.
37. Arends M.J., Morris R.G., Wyllie A.H. Apoptosis. The role of the endonuclease. Am. J. Pathol. (1990) 136 593-608.
38. Wyllie A.H. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (1980) 284 555-556.
39. New D.A. Whole-embryo culture and the study of mammalian embryos during organogenesis. Biol. Rev. Camb. Philos. Soc. (1978) 53 81-122.
40. Chernoff N., Rogers J.M., Alles A.J. et al. Cell cycle alterations and cell death in cyclophosphamide teratogenesis. Teratog. Carcinog. Mutagen. (1989) 9 199-209.
41. Tilly J.L., Hsueh A.J. Microscale autoradiographic method for the qualitative and quantitative analysis of apoptotic DNA fragmentation. J. Cell. Physiol. (1993) 154 519-526.
42. Darzynkiewicz Z., Juan G., Li X., Gorczyca W., Murakami T., Traganos F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry (1997) 27 1-20.
43. Del Bino G., Darzynkiewicz Z., Degraef C., Mosselmans R., Fokan D., Galand P. Comparison of methods based on annexin-V binding, DNA content or TUNEL for evaluating cell death in HL-60 and adherent MCF-7 cells. Cell Prolif. (1999) 32 25-37.
44. Allen V.M., Armson B.A., Wilson R.D. et al. Teratogenicity associated with pre-existing and gestational diabetes. J. Obstet. Gynaecol. Can. (2007) 29 927-944.
45. Corrigan N., Brazil D.P., McAuliffe F. Fetal cardiac effects of maternal hyperglycemia during pregnancy. Birth Defects Res. A Clin. Mol. Teratol. (2009) 85 523-530.
46. Efanova I.B., Zaitsev S.V., Zhivotovsky B. et al. Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J. Biol. Chem. (1998) 273 33501-33507.
47. Marchetti P., Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clin. Pharmacokinet. (1989) 16 100-128.
48. Yu W., Niwa T., Miura Y. et al. Calmodulin overexpression causes Ca(2+)-dependent apoptosis of pancreatic beta cells, which can be prevented by inhibition of nitric oxide synthase. Lab. Invest. (2002) 82 1229-1239.
49. Sturgess N.C., Ashford M.L., Cook D.L., Hales C.N. The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet (1985) 2 474-475.
50. Ashford M.L., Sturgess N.C., Trout N.J., Gardner N.J., Hales C.N. Adenosine-5′-triphosphate-sensitive ion channels in neonatal rat cultured central neurones. Pflugers Arch. (1988) 412 297-304.
51. Noma A. ATP-regulated K+ channels in cardiac muscle. Nature (1983) 305 147-148.
52. Spruce A.E., Standen N.B., Stanfield P.R. Voltage-dependent ATP-sensitive potassium channels of skeletal muscle membrane. Nature (1985) 316 736-738.
53. Standen N.B., Quayle J.M., Davies N.W., Brayden J.E., Huang Y., Nelson M.T. Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth muscle. Science (1989) 245 177-180.
54. Gier B., Krippeit-Drews P., Sheiko T. et al. Suppression of KATP channel activity protects murine pancreatic beta cells against oxidative stress. J. Clin. Invest. (2009) 119 3246-3256.
55. Takahashi A., Nagashima K., Hamasaki A. et al. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. Diabetes Res. Clin. Pract. (2007) 77 343-350.
56. Gomez-Lechon M.J., O'Connor E., Castell J.V., Jover R. Sensitive markers used to identify compounds that trigger apoptosis in cultured hepatocytes. Toxicol. Sci. (2002) 65 299-308.
57. Lennon S.V., Martin S.J., Cotter T.G. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif. (1991) 24 203-214.